The effects of chamomile capsule on menstrual patterns and hormones and lipid parameters in woman with poly cystic ovarian syndrom

The effects of chamomile capsule in improving menstrual patterns and hormones and lipid parameters in woman of reproductive age with poly cystic ovarian syndrom

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014060217958N1

Enrollment

Registered

2014-10-25

Start date

2014-06-14

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovarian Syndrom. Polycystic Ovarian Syndrome

Interventions

Intervention 1: In the intervention group,Chammomile capsules 370 mg,Three times a day,For 12 weeks. Intervention 2: In the control group,370 mg Placebo,Three times a day? ?or 12 weeks.

Treatment - Drugs

In the intervention group,Chammomile capsules 370 mg,Three times a day,For 12 weeks

In the control group,370 mg Placebo,Three times a day? ?or 12 weeks

Eligibility

Sex/Gender

Female

Age

15 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria:women whom have poly cystic ovarian syndrome that identify with gynecologist and endocrinologist? Having oligomenorrhea and second amenorrhea Exclusion criteria: having gastrointestinal? Liver?Kidney diseases?Convulsion?Allergic?Asthma?having the history of endometrial hyperplasia or breast cancer? taking the hormonal medicine from one month ago? having infertility? having AUB? Having allergic drug reaction? Can not continue taking medicine? High FSH hormone and early menopose Taking anti coagulant drugs.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
FSH. Timepoint: before and after of therapy. Method of measurement: sampling.;T Total. Timepoint: before and after of therapy. Method of measurement: sampling.;DHEAS. Timepoint: before and after of therapy. Method of measurement: sampling.;Menstural pattern. Timepoint: before and after of therapy. Method of measurement: questionnaire.;LH. Timepoint: before and after of therapy. Method of measurement: sampling.;TG. Timepoint: before and after of therapy. Method of measurement: sampling.;HDL. Timepoint: before and after of therapy. Method of measurement: sampling.	—

Measure

Time frame

FSH. Timepoint: before and after of therapy. Method of measurement: sampling.;T Total. Timepoint: before and after of therapy. Method of measurement: sampling.;DHEAS. Timepoint: before and after of therapy. Method of measurement: sampling.;Menstural pattern. Timepoint: before and after of therapy. Method of measurement: questionnaire.;LH. Timepoint: before and after of therapy. Method of measurement: sampling.;TG. Timepoint: before and after of therapy. Method of measurement: sampling.;HDL. Timepoint: before and after of therapy. Method of measurement: sampling.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Heidary

Shiraz University of Medical Sciences

Maryam_mid2000@yahoo.com+98 71 3647 4252

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026